PT3101026T - Compostos para a inibição enzimática de proteassomas - Google Patents

Compostos para a inibição enzimática de proteassomas

Info

Publication number
PT3101026T
PT3101026T PT161664925T PT16166492T PT3101026T PT 3101026 T PT3101026 T PT 3101026T PT 161664925 T PT161664925 T PT 161664925T PT 16166492 T PT16166492 T PT 16166492T PT 3101026 T PT3101026 T PT 3101026T
Authority
PT
Portugal
Prior art keywords
compounds
peptide
based compounds
activities
ntn
Prior art date
Application number
PT161664925T
Other languages
English (en)
Portuguese (pt)
Inventor
S Smyth Mark
J Laidig Guy
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3101026(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of PT3101026T publication Critical patent/PT3101026T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
PT161664925T 2004-08-06 2005-08-08 Compostos para a inibição enzimática de proteassomas PT3101026T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59940104P 2004-08-06 2004-08-06
US61000104P 2004-09-14 2004-09-14
US11/106,879 US7232818B2 (en) 2004-04-15 2005-04-14 Compounds for enzyme inhibition

Publications (1)

Publication Number Publication Date
PT3101026T true PT3101026T (pt) 2018-08-03

Family

ID=35502451

Family Applications (2)

Application Number Title Priority Date Filing Date
PT161664925T PT3101026T (pt) 2004-08-06 2005-08-08 Compostos para a inibição enzimática de proteassomas
PT05784484T PT1781688E (pt) 2004-08-06 2005-08-08 Compostos para a inibição enzimática de proteassomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT05784484T PT1781688E (pt) 2004-08-06 2005-08-08 Compostos para a inibição enzimática de proteassomas

Country Status (24)

Country Link
US (12) US7232818B2 (cg-RX-API-DMAC10.html)
EP (4) EP1781688B1 (cg-RX-API-DMAC10.html)
JP (2) JP4743720B2 (cg-RX-API-DMAC10.html)
KR (3) KR101544258B1 (cg-RX-API-DMAC10.html)
CN (1) CN102286070B (cg-RX-API-DMAC10.html)
AT (1) ATE496062T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005271232B2 (cg-RX-API-DMAC10.html)
BR (2) BR122020008634B8 (cg-RX-API-DMAC10.html)
CA (1) CA2589765C (cg-RX-API-DMAC10.html)
CY (3) CY1116771T1 (cg-RX-API-DMAC10.html)
DE (1) DE602005026019D1 (cg-RX-API-DMAC10.html)
DK (2) DK1781688T3 (cg-RX-API-DMAC10.html)
ES (2) ES2674277T3 (cg-RX-API-DMAC10.html)
FR (1) FR16C0017I2 (cg-RX-API-DMAC10.html)
HU (2) HUE038005T2 (cg-RX-API-DMAC10.html)
IL (3) IL181127A (cg-RX-API-DMAC10.html)
LT (2) LT3101026T (cg-RX-API-DMAC10.html)
LU (1) LU93015I2 (cg-RX-API-DMAC10.html)
NO (2) NO341015B1 (cg-RX-API-DMAC10.html)
PL (2) PL1781688T3 (cg-RX-API-DMAC10.html)
PT (2) PT3101026T (cg-RX-API-DMAC10.html)
SG (2) SG10201701794UA (cg-RX-API-DMAC10.html)
SI (2) SI3101026T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006017842A1 (cg-RX-API-DMAC10.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
AU2005243140A1 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
MX2007006526A (es) 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
KR101299821B1 (ko) * 2004-12-07 2013-09-03 프로테올릭스, 인코퍼레이티드 프로테아좀 저해를 위한 조성물
MX2008006090A (es) * 2005-11-09 2008-10-23 Proteolix Inc Compuestos para inhibicion de la enzima.
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
WO2008006819A2 (en) * 2006-07-14 2008-01-17 Vib Vzw Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
AU2016231532B2 (en) * 2007-10-04 2018-05-10 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
KR20160086980A (ko) * 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
AU2013203566B2 (en) * 2007-10-04 2016-10-13 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2723465A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110009332A1 (en) * 2009-07-09 2011-01-13 Southwest Research Institute Therapeutic Treatment Of Wounds
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
EP2555621A4 (en) 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
WO2013009923A1 (en) * 2011-07-13 2013-01-17 Creighton University Methods of promoting neuron growth
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
SMT202400264T1 (it) 2012-05-08 2024-07-09 Onyx Therapeutics Inc Metodi di complessazione di ciclodestrina per formulare inibitori del proteasoma peptidico
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
MX363455B (es) 2012-07-18 2019-03-25 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
WO2014029022A1 (en) * 2012-08-21 2014-02-27 Abdelmalik Slassi Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
HK1213585A1 (zh) 2012-10-22 2016-07-08 Cydex Pharmaceuticals, Inc. 烷基化环糊精组合物及其制备和使用方法
PL2968555T3 (pl) 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP2970225B1 (en) 2013-03-14 2018-08-15 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
MX372671B (es) 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
US20160215016A1 (en) * 2013-09-06 2016-07-28 Sandoz Ag Synthesis of peptide epoxy ketones
CA2922210A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN103864889B (zh) * 2014-04-04 2017-01-11 重庆泰濠制药有限公司 环氧酮化合物、其制备方法及卡非佐米的制备方法
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) * 2014-11-24 2015-03-11 重庆泰濠制药有限公司 一种卡非佐米无定型晶的制备方法
EP3227312B1 (en) 2014-12-02 2019-05-29 Fresenius Kabi Oncology Limited A process for purification of carfilzomib
US10301353B2 (en) 2014-12-31 2019-05-28 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US10544189B2 (en) 2015-04-22 2020-01-28 Msn Laboratories Private Limited Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
US10364269B2 (en) 2015-05-21 2019-07-30 Laurus Labs Limited Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CN106317188A (zh) * 2015-06-18 2017-01-11 重庆医药工业研究院有限责任公司 一种制备卡非佐米无定型物的方法
WO2017032487A1 (en) 2015-08-27 2017-03-02 Technische Universität München Proteasome inhibitor comprising a signal-emitting moiety
WO2017098532A1 (en) 2015-12-11 2017-06-15 Mylan Laboratories Limited Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) * 2015-12-31 2018-09-21 中化合成生技股份有限公司 無定形卡非佐米(i)的製備方法
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
EP3494108B1 (en) 2016-08-05 2020-10-28 Amgen Inc. Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
EP3512835B1 (en) 2016-09-14 2021-06-09 Fresenius Kabi Oncology Limited A process for purification of carfilzomib intermediate
ES2978159T3 (es) 2016-09-16 2024-09-06 Hsf Pharmaceuticals Inhibidores de factores de choque térmico (HSF) y usos de los mismos
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
MX2020004936A (es) 2017-11-16 2020-08-27 Amgen Inc Composiciones estables de compuestos de carfilzomib pegilado.
CN111699386B (zh) * 2017-12-08 2023-08-18 神经Gx有限责任公司 用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019133988A1 (en) 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
SG11202012765PA (en) * 2018-06-22 2021-01-28 Ucl Business Ltd Novel compounds
WO2021072212A1 (en) * 2019-10-11 2021-04-15 Mayo Foundation For Medical Education And Research Proteasome inhibitors
WO2021216670A1 (en) * 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024069240A2 (en) 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Cd38-binding fusion protein combination therapy
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN116768972A (zh) * 2023-06-25 2023-09-19 重庆药友制药有限责任公司 一种卡非佐米中间体的制备方法
WO2025035020A2 (en) 2023-08-09 2025-02-13 Amgen Inc. Methods of using carfilzomib
EP4685151A1 (en) 2024-07-24 2026-01-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569748A (en) 1896-10-20 Henry edmunds
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1716861A3 (en) 1999-10-20 2007-08-29 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2003059898A2 (en) 2002-01-08 2003-07-24 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2005105827A2 (en) * 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
AU2005243140A1 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
JP5108509B2 (ja) 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物

Also Published As

Publication number Publication date
US7491704B2 (en) 2009-02-17
LTPA2016010I1 (lt) 2016-04-25
EP2270026A3 (en) 2011-09-14
KR20070047780A (ko) 2007-05-07
IL181127A0 (en) 2007-07-04
CN102286070A (zh) 2011-12-21
US20150361134A1 (en) 2015-12-17
LTC1781688I2 (lt) 2017-09-25
WO2006017842A1 (en) 2006-02-16
NO20170381A1 (no) 2007-04-16
US20160222057A1 (en) 2016-08-04
AU2005271232B2 (en) 2012-07-05
US20200071356A1 (en) 2020-03-05
HUE038005T2 (hu) 2018-09-28
FR16C0017I2 (fr) 2016-08-26
JP5394423B2 (ja) 2014-01-22
EP1781688A1 (en) 2007-05-09
CY2016009I2 (el) 2016-08-31
IL261892A (en) 2018-10-31
CA2589765C (en) 2015-06-30
BRPI0514102B8 (pt) 2021-05-25
SG155187A1 (en) 2009-09-30
NO344397B1 (no) 2019-11-25
AU2005271232A1 (en) 2006-02-16
EP2270026A2 (en) 2011-01-05
HK1152536A1 (en) 2012-03-02
KR101354280B1 (ko) 2014-01-23
US20140342977A1 (en) 2014-11-20
CY2016009I1 (el) 2016-08-31
PT1781688E (pt) 2011-04-05
CY1116771T1 (el) 2016-08-31
BRPI0514102B1 (pt) 2020-07-07
DK3101026T3 (en) 2018-06-18
FR16C0017I1 (cg-RX-API-DMAC10.html) 2016-06-24
IL221572A0 (en) 2012-10-31
EP2270026B1 (en) 2016-05-18
NO341015B1 (no) 2017-08-07
EP1781688B1 (en) 2011-01-19
ATE496062T1 (de) 2011-02-15
CN102286070B (zh) 2014-12-10
US20060030533A1 (en) 2006-02-09
IL181127A (en) 2013-03-24
US20070191284A1 (en) 2007-08-16
IL261892B (en) 2019-12-31
HK1152716A1 (en) 2012-03-09
US20190211058A1 (en) 2019-07-11
JP2008509166A (ja) 2008-03-27
PL3101026T3 (pl) 2018-12-31
EP2266999A2 (en) 2010-12-29
PL1781688T3 (pl) 2011-06-30
CA2589765A1 (en) 2006-02-16
CY1120677T1 (el) 2019-12-11
EP3101026A1 (en) 2016-12-07
IL221572B (en) 2018-10-31
US20220267372A1 (en) 2022-08-25
BRPI0514102A (pt) 2008-05-27
ES2525248T3 (es) 2014-12-19
EP3101026B1 (en) 2018-03-28
DE602005026019D1 (de) 2011-03-03
BR122020008634B8 (pt) 2021-07-27
KR20130080064A (ko) 2013-07-11
HK1231491A1 (en) 2017-12-22
HUS1600014I1 (hu) 2016-05-30
SI1781688T1 (sl) 2011-05-31
BR122020008634B1 (pt) 2021-02-17
LT3101026T (lt) 2018-07-10
DK1781688T3 (da) 2011-03-14
LU93015I2 (fr) 2016-06-06
US20200325172A1 (en) 2020-10-15
US20210179663A1 (en) 2021-06-17
EP2266999B1 (en) 2014-09-24
SG10201701794UA (en) 2017-04-27
HK1103525A1 (en) 2007-12-21
JP2011148805A (ja) 2011-08-04
ES2674277T3 (es) 2018-06-28
KR20120135355A (ko) 2012-12-12
US20180170962A1 (en) 2018-06-21
EP2266999A3 (en) 2011-09-14
US20050245435A1 (en) 2005-11-03
US7232818B2 (en) 2007-06-19
NO20070965L (no) 2007-04-16
JP4743720B2 (ja) 2011-08-10
US7417042B2 (en) 2008-08-26
KR101544258B1 (ko) 2015-08-21
SI3101026T1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
HUS1600014I1 (hu) Vegyületek proteasztómális enzimek gátlására
IL217210A0 (en) Compounds for proteasome enzyme inhibition
EP2564834A3 (en) Compounds for Proteasome Enzyme Inhibition
MY145757A (en) Compounds for enzyme inhibition
WO2008140782A3 (en) Compounds for enzyme inhibition
WO2006045066A3 (en) Labeled compounds for proteasome inhibition
CR9962A (es) Compuestos para inhibicion enzimatica